Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques DOI Creative Commons
Pirangi Srikanth, Khaja Moinuddin Shaik,

Vijay Patibandla

и другие.

Опубликована: Март 25, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly emerging as a global health crisis, affecting over 30% of the population and demanding urgent attention. This redefined condition, previously known non-alcoholic fatty (NAFLD), reflects deeper understanding intricate interplay between metabolic dysfunction health. At heart MASLD lies troubling accumulation triglycerides (TGs) in hepatocytes, which precipitates insulin resistance oxidative stress, ultimately leading to more severe forms like steatohepatitis (MASH). Excitingly, recent research has spotlighted farnesoid X receptor (FXR) groundbreaking therapeutic target. FXR not only regulates lipid metabolism but also combats inflammation resistance, making it potential game-changer fight against MASLD. With one FDA-approved drug, resmetirom, currently available, exploration agonists opens new avenues for innovative treatments that could revolutionize patient care. By harnessing power restore balance integrating advanced strategies lipidomics acid profiling, we stand on brink transforming how approach its associated complications, paving way healthier future. review delves into promising role combating implications related disorders, emphasizing urgency detect manage this burgeoning epidemic.

Язык: Английский

From Liking to Following: The Role of Food Preferences, Taste Perception, and Lifestyle Factors in Adherence to the Mediterranean Diet Among Young Individuals DOI Open Access
José V. Sorlí,

Edurne de la Cámara,

José Ignacio González Arráez

и другие.

Nutrients, Год журнала: 2025, Номер 17(3), С. 600 - 600

Опубликована: Фев. 6, 2025

Background and aims: The Mediterranean diet (MedDiet) is a healthy dietary pattern associated with reduced risk of chronic diseases. However, adherence declining, particularly among younger populations. Therefore, it crucial to identify the main aspects that affect its adherence, food preferences sensory function, which have received insufficient attention. Our aims were investigate impact socio-demographic lifestyle factors on MedDiet young individuals; assess association taste liking adherence; evaluate associations between perception modalities, preferences, adherence. Methods: A cross-sectional study adults (aged 20.5 ± 4.7 years) in country (n = 879) was carried out. Demographic characteristics, clinical anthropometric assessed. Taste for bitter, salty, sweet, sour, umami determined by rating different concentrations prototypical tastants. We computed total score three scores combine preferences. Results: identified several MedDiet, as well determinants. Food significantly MedDiet. Higher preference olive oil, oranges, broccoli, fish, legumes higher (p < 0.05 all). Conversely, sweet foods, red meat, butter lower combined positive strongly 1.4 × 10−23) multivariate adjusted model. negative inversely 1.9 10−8). Likewise, (strong inverse direct bitter preference; both p 0.001). Moreover, foods 0.05). In conclusion, future precision nutrition studies should measure are determinants especially people.

Язык: Английский

Процитировано

0

Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques DOI Creative Commons
Pirangi Srikanth, Khaja Moinuddin Shaik,

Vijay Patibandla

и другие.

Опубликована: Март 25, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly emerging as a global health crisis, affecting over 30% of the population and demanding urgent attention. This redefined condition, previously known non-alcoholic fatty (NAFLD), reflects deeper understanding intricate interplay between metabolic dysfunction health. At heart MASLD lies troubling accumulation triglycerides (TGs) in hepatocytes, which precipitates insulin resistance oxidative stress, ultimately leading to more severe forms like steatohepatitis (MASH). Excitingly, recent research has spotlighted farnesoid X receptor (FXR) groundbreaking therapeutic target. FXR not only regulates lipid metabolism but also combats inflammation resistance, making it potential game-changer fight against MASLD. With one FDA-approved drug, resmetirom, currently available, exploration agonists opens new avenues for innovative treatments that could revolutionize patient care. By harnessing power restore balance integrating advanced strategies lipidomics acid profiling, we stand on brink transforming how approach its associated complications, paving way healthier future. review delves into promising role combating implications related disorders, emphasizing urgency detect manage this burgeoning epidemic.

Язык: Английский

Процитировано

0